Literature DB >> 7227651

Response of children to a single dose of oral or inactivated polio vaccine.

D Magrath, D Bainton, M Freeman.   

Abstract

Approximately 200 children aged 8, 12 and 16 years with poliovirus neutralising antibody titres of less than 1/45 to at least one type were given a single dose of oral or inactivated polio vaccine. Almost all children given IPV responded with high levels of neutralising antibody to all 3 types. The response to the oral vaccine was less dramatic. The relationship between pre-existing antibody and the further response and the implications for susceptibility to reinfection will be discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7227651

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  5 in total

1.  Immunity to poliovirus serotypes in children population of selected communities in South-west, Nigeria.

Authors:  Johnson Adekunle Adeniji; Folakemi Abiodun Osundare; Olubusuyi Moses Adewumi; Anyebe Bernard Onoja; Ademola Hezekiah Fagbami
Journal:  Afr J Infect Dis       Date:  2015

2.  Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity.

Authors:  S Tang; R van Rij; D Silvera; R Andino
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen.

Authors:  S Mandl; L J Sigal; K L Rock; R Andino
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

Review 4.  Interrupting the transmission of wild polioviruses with vaccines: immunological considerations.

Authors:  Y Ghendon; S E Robertson
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

5.  Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines.

Authors:  Yuhong Xiao; Henry Daniell
Journal:  Vaccine       Date:  2017-01-19       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.